Chinese pharmaceutical companies signed a record US$136 billion worth of out licensing agreements in 2025, underscoring the rapid rise of China as a major source of innovative drug development and reshaping the global biopharmaceutical landscape. According to industry analysts, the total value of
China is accelerating efforts to merge artificial intelligence with healthcare, positioning the combination as a cornerstone of its long term vision for an intelligent society. Under a national plan released in October, Beijing has placed AI-driven healthcare innovation at the center of public
China’s biotech sector is making significant strides in addressing rare diseases through research, innovation, and advanced laboratory techniques. Rare diseases, often genetic in origin, affect a small percentage of the population but present complex challenges for diagnosis, treatment, and drug development. Chinese biotech
Gene therapy represents one of the most promising frontiers in modern medicine, offering solutions to previously untreatable genetic disorders. In China, young entrepreneurs are leading the way in developing innovative therapies, and Guo Chen, a 28-year-old biotech entrepreneur, stands out as a pioneering
Women executives are increasingly shaping the biotech and healthcare sectors in China, driving innovation, strategic growth, and operational excellence. Their leadership spans pharmaceutical research, medical technology, digital health platforms, and biotechnology startups. These leaders are breaking traditional gender barriers while steering organizations through
